Saturday, October 31, 2026

Energy & Resources

2 articles

U.S. Solar Chief Faces Collapse Risk as Chinese Competition Exposes Policy Dependency

U.S. Solar Chief Faces Collapse Risk as Chinese Competition Exposes Policy Dependency

Suniva CEO Tony Etnyre faces a catastrophic-severity risk: U.S. domestic solar cell manufacturing is economically unviable without Section 201/301 tariffs and IRA tax credits. China's cost dominance in global solar production means American factories have no competitive fallback if either policy pillar is removed. For international investors with exposure to U.S. solar assets, the risk profile is binary — viability or collapse.

LM Salvado•
U.S. Bets on New York Graphite Mine to Break China's Stranglehold on Battery Supply Chains

U.S. Bets on New York Graphite Mine to Break China's Stranglehold on Battery Supply Chains

Titan Mining's Kilbourne Graphite Project in upstate New York is emerging as a flagship effort to reduce Western dependence on Chinese graphite, which dominates global supply of a mineral critical to electric vehicle batteries. Backed by $120 million in U.S. federal financing and boasting a $513 million after-tax NPV, the project targets 2027 construction and could supply roughly half of current U.S. natural graphite demand by itself. The development reflects a broader geopolitical push by Washi

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com